ATE521339T1 - Pharmazeutische zusammensetzung aus venlafaxin- hydrochlorid mit kontrollierter freisetzung und herstellungsverfahren dafür - Google Patents

Pharmazeutische zusammensetzung aus venlafaxin- hydrochlorid mit kontrollierter freisetzung und herstellungsverfahren dafür

Info

Publication number
ATE521339T1
ATE521339T1 AT06819063T AT06819063T ATE521339T1 AT E521339 T1 ATE521339 T1 AT E521339T1 AT 06819063 T AT06819063 T AT 06819063T AT 06819063 T AT06819063 T AT 06819063T AT E521339 T1 ATE521339 T1 AT E521339T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
controlled release
release pharmaceutical
venlafaxine hydrochloride
production method
Prior art date
Application number
AT06819063T
Other languages
English (en)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Original Assignee
Valpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma Sa filed Critical Valpharma Sa
Application granted granted Critical
Publication of ATE521339T1 publication Critical patent/ATE521339T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06819063T 2005-09-30 2006-09-29 Pharmazeutische zusammensetzung aus venlafaxin- hydrochlorid mit kontrollierter freisetzung und herstellungsverfahren dafür ATE521339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITFI20050206A1 (it) 2005-09-30 2005-09-30 Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
PCT/EP2006/066906 WO2007039569A2 (en) 2005-09-30 2006-09-29 Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof

Publications (1)

Publication Number Publication Date
ATE521339T1 true ATE521339T1 (de) 2011-09-15

Family

ID=36215990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06819063T ATE521339T1 (de) 2005-09-30 2006-09-29 Pharmazeutische zusammensetzung aus venlafaxin- hydrochlorid mit kontrollierter freisetzung und herstellungsverfahren dafür

Country Status (17)

Country Link
US (1) US20090263471A1 (de)
EP (1) EP1928424B1 (de)
JP (1) JP2009510027A (de)
KR (1) KR20080047557A (de)
CN (1) CN101257893A (de)
AT (1) ATE521339T1 (de)
AU (1) AU2006298693A1 (de)
BR (1) BRPI0616276A2 (de)
CA (1) CA2622822A1 (de)
ES (1) ES2373164T3 (de)
IL (1) IL190305A0 (de)
IT (1) ITFI20050206A1 (de)
NO (1) NO20081733L (de)
NZ (1) NZ567735A (de)
RU (1) RU2423105C2 (de)
WO (1) WO2007039569A2 (de)
ZA (1) ZA200803502B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CN102085197B (zh) * 2010-12-14 2013-08-14 北京万生药业有限责任公司 一种文拉法辛缓释制剂及其制备方法
CN103181916A (zh) * 2011-12-30 2013-07-03 昆明积大制药股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
HK1054195B (zh) * 2001-02-27 2005-09-09 Evonik Röhm Gmbh 用於提高了儲存穩定性的藥物製劑的包衣及粘合劑
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US6703044B1 (en) * 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
ZA200505180B (en) * 2002-11-28 2006-10-25 Themis Lab Private Ltd Process for manufacturing sustained release microbeads containing venlafaxine HCI

Also Published As

Publication number Publication date
US20090263471A1 (en) 2009-10-22
ES2373164T3 (es) 2012-02-01
EP1928424A2 (de) 2008-06-11
ZA200803502B (en) 2009-01-28
CA2622822A1 (en) 2007-04-12
CN101257893A (zh) 2008-09-03
EP1928424B1 (de) 2011-08-24
BRPI0616276A2 (pt) 2011-06-14
WO2007039569A2 (en) 2007-04-12
ITFI20050206A1 (it) 2007-04-01
NO20081733L (no) 2008-04-07
JP2009510027A (ja) 2009-03-12
AU2006298693A1 (en) 2007-04-12
WO2007039569A3 (en) 2007-07-26
RU2423105C2 (ru) 2011-07-10
IL190305A0 (en) 2009-09-22
KR20080047557A (ko) 2008-05-29
NZ567735A (en) 2011-03-31
RU2008117111A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
ZA200803502B (en) Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof
MX2012007046A (es) Microcapsulas de silice de liberacion sostenida.
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
PE20060195A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
WO2005104744A3 (en) Method for forming structures using an encapsulated adhesive material
CL2013002226A1 (es) Proceso para preparar (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida estereometricamente enriquecida o una sal farmaceuticamente aceptable de ella por resolucion dinamica secuencial y animacion reductiva de una octan-3-ona.
UA88168C2 (uk) Препарат у вигляді таблетки саксагліптину з покриттям і спосіб його виготовлення
BRPI0409652A (pt) tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
ATE476176T1 (de) Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
JP2007527914A5 (de)
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
CL2007002141A1 (es) Aparato para formar nucleos absorbentes depositados por aire, abarcando una primera y segunda rueda formadoras de esteras; metodo de formacion de centros absorbentes.
EG25586A (en) Coated fertiliser with a controlled release of active ingredients, and method for the production thereof
DE60232189D1 (de) Zusammensetzungen mit verzögerter freigabe enthaltend venlafaxinhydrochlorid als wirkstoff
ATE378042T1 (de) Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
EP4205745A4 (de) Pharmazeutische cariprazinzusammensetzung, herstellungsverfahren und anwendung davon
AR065342A1 (es) Composiciones farmaceuticas que contienen fumarato de quetiapina
WO2006137856A3 (en) Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
ATE418969T1 (de) Carvedilol enthaltende pharmazeutische zusammensetzung mit kontrollierter freisetzung
JP2008520195A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties